AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. Its lead product candidate is DSUVIA and DZUVEO, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. The company develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain; ARX-02, which is in Phase 2 clinical trial for the treatment of cancer breakthrough pain in opioid-tolerant patients; and 4ARX-03 for mild sedation and pain relief during painful procedures. Its product candidates also include Niyad, a regional anticoagulant for the extracorporeal circuit; and LTX-608, a nafamostat formulation for direct IV infusion being explored as an investigational product for antiviral treatment of COVID, acute respiratory distress syndrome, disseminated intravascular coagulation, and acute pancreatitis. The company was formerly known as SuRx, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was incorporated in 2005 and is based in Hayward, California.
Earnings for AcelRx Pharmaceuticals, Inc. (ACRX)
Earnings in 2023 (TTM): $-10,287,000
According to AcelRx Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-10,287,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of AcelRx Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-10,287,000 | $-10,287,000 |
| 2022 | $47.77 M | $47.76 M |
| 2021 | $-35,094,000 | $-35,099,000 |
| 2020 | $-40,375,000 | $-40,379,000 |
| 2019 | $-53,237,000 | $-53,240,000 |
| 2018 | $-47,147,000 | $-47,149,000 |
| 2017 | $-52,209,000 | $-51,508,000 |
| 2016 | $-43,191,000 | $-43,157,000 |
| 2015 | $-23,639,000 | $-24,399,000 |
| 2014 | $-33,353,000 | $-33,353,000 |
| 2013 | $-23,426,000 | $-23,426,000 |
| 2012 | $-33,363,000 | $-33,363,000 |
| 2011 | $-20,101,000 | $-20,101,000 |
| 2010 | $-14,344,000 | $-14,344,000 |
| 2009 | $-20,119,000 | $-20,119,000 |
| 2008 | $-20,662,000 | $-20,662,000 |